Table 3.

First switch to second-line treatment in patients with prostate cancer prescribed first-line degarelix, leuprorelin, goserelin or triptorelin

Parameter	Degarelix users n = 101	Leuprorelin n = 3289	Goserelin n = 4366	Triptorelin n = 1325
Switched to second-line treatment
n (%)	34 (33.7)	221 (6.7)	812 (18.6)	98 (7.4)
Time to switch from initiation therapy to second-line treatment, days
Mean (SD)	289.8 (261.5)	453.6 (538.4)	559.1 (542.2)	354.2 (448.1)
Median (IQR)	234.0 (53.0–448.0)	280.0 (84.0–587.0)	378.0 (121.0–810.0)	167.0 (84.0–453.0)

IQR interquartile range, SD standard deviation